“The goal of diagnosing and treating prostate cancer is diagnosing it early on when it’s confined to the prostate”
NEW YORK, NY–(Marketwired – Sep 7, 2016) – During their lifetime approximately one in seven men will be diagnosed with prostate cancer, the second most common cancer among men in the U.S. The odds increase for African Americans and double for those with a family history of the disease.
Posted by 4Kscore on Sep 14, 2016 12:00:00 PM
OPKO Health, Inc. (NYSE: OPK) announced today the results of a study for the 4Kscore® Test’s clinical utility in reducing the number of prostate biopsies performed, while increasing the probability of detecting aggressive prostate cancer in men with abnormal prostate-specific antigen (PSA) levels and or digital rectal examination (DRE) results. The peer-reviewed study, “The 4Kscore® Test Reduces Prostate Biopsy Rates in Community and Academic Urology Practices”, written by Badrinath Konety, MD, et al. and published in the January 2016 edition of Reviews in Urology, a MedReviews, LLC. Publication, which included 611 patients seen by 35 academic and community urologists across the United States, indicated that consideration of results from the 4Kscore tests led to 64.6% fewer prostate biopsies being performed among participating patients.
Posted by 4Kscore on Feb 9, 2016 12:00:00 PM
A blood test called the 4Kscore results in accurate detection of high-grade prostate cancer. In a prospective study of 1,012 men, this test more accurately predicted the presence of high-grade disease compared with a commonly used risk calculator in men with elevated prostate-specific antigen (PSA) levels.
The results from this study (Abstract 1) were presented by Sanoj Punnen, MD, a urologic oncologist at the University of Miami in Florida at the 2015 Genitourinary Cancers Symposium.
In this study, men scheduled for a prostate biopsy were enrolled, regardless of their PSA level or clinical findings, at 26 centers across the United States between October 2013 and April 2014. A total of 231 (23%) high-grade prostate cancers were detected. The 4Kscore showed a higher net benefit in comparison with the PCPTRC at all threshold possibilities for high-grade disease used in clinical practice.
Posted by 4Kscore on Dec 14, 2015 12:00:00 PM
ORLANDO—The 4Kscore, an algorithmic analysis of data from a blood test that combines four kallikrein assays with clinical information to identify the probability of high-grade prostate tumors, could dramatically reduce the number of unnecessary prostate biopsies, according to a multi-institutional prospective study (Abstract 1) presented during the 2015 Genitourinary Cancers Symposium.1
Posted by 4Kscore on Dec 8, 2015 12:00:00 PM
Click here to learn how the 4Kscore Test is helping clarify the biopsy decision.
